Palatin Technologies (NYSE American: PTN) is a clinical-stage biopharmaceutical company that discovers and develops peptide-based therapeutics targeting melanocortin receptors. The company has generated no product revenue and funds operations through equity issuances, including common stock and warrant sales. Palatin's lead candidate is PL9643, a peptide melanocortin agonist active at MC1R and MC5R receptors, formulated as a topical ophthalmic solution for dry eye disease (keratoconjunctivitis sicca), a condition estimated to affect over 30 million people in the United States. A Phase 3 pivotal trial (MELODY-1) was completed with positive top-line results on the co-primary symptom endpoint of pain (p<0.025), though co-primary sign endpoints did not achieve statistical significance. Palatin reported a net loss of $17,307,349 for fiscal year 2025 and has incurred cumulative losses since inception. The company is headquartered in Princeton, New Jersey, with laboratory space in Monmouth Junction, New Jersey. Carl Spana, Ph.D. serves as Chief Executive Officer and President.

Revenue model

Palatin has no product revenue. Operations are funded through equity financings: in fiscal 2025, net cash from financing activities was $11,213,506, consisting of $7,960,765 from common stock and warrant sales (net of issuance costs) and $3,398,237 from warrant exercises. The company anticipates future revenue from potential licensing milestones and product sales if regulatory approvals are obtained.

Products and services

PL9643: a peptide melanocortin agonist targeting MC1R and MC5R, developed as a single-use ophthalmic solution for dry eye disease and other anti-inflammatory ocular indications. Phase 3 MELODY-1 trial completed with positive symptom endpoint results as of the 10-K filed September 23, 2025. Additional melanocortin receptor (MCR) product candidates are in development.

Customers and end markets

End market is patients with dry eye disease, a condition estimated to affect over 30 million people in the United States. Reimbursement is expected to come from private insurers, HMOs, and government payers. European markets, if entered, would require country-by-country pricing and reimbursement negotiations.

Value-chain role

Early-stage drug developer occupying the discovery, preclinical, and clinical development segments of the pharmaceutical value chain. Palatin does not manufacture at commercial scale or distribute products. Commercialization is expected to involve marketing partners or licensees.

Geographic exposure

Headquartered in Princeton, New Jersey. Laboratory space in Monmouth Junction, New Jersey. Clinical and regulatory activities are U.S.-focused, with potential European market entry referenced but not yet active as of the fiscal 2025 filing.

Source: SEC 10-K, filed 2025-09-23

Industry: Pharmaceutical Preparations Peers: Akebia Therapeutics Inc Atreca, Inc. BioVie Inc Unity Biotechnology, Inc. Disc Medicine Inc GT Biopharma Inc EOM Pharmaceutical Holdings, Inc. Surface Oncology, Inc. Solid Biosciences Inc